Highest-materiality recent filing
Viemed Q2 2026 revenue $78.1M record, up 23.9% YoY; raises FY revenue guidance
Net revenue $78.1M (record), up 23.9% YoY; net income $2.8M ($0.07 diluted EPS).
Viemed Healthcare reports Q1 2026 revenue of $75.4M, raises full-year guidance
Net revenues increased 28% to $75.4 million for Q1 2026, up from $59.1 million in Q1 2025.
Viemed posts record FY2025 revenue $270.3M; net income +33%; guides FY2026 rev $310-320M
Q4 revenue $76.2M (record, +26% YoY); FY revenue $270.3M (record, +21% YoY).
Viemed Q3 revenue record $71.9M, up 24% YoY; guides FY rev $271-273M
Net revenues $71.9M, a company record, up 24% YoY from $58.0M.
Viemed Q2 net revenue $63.1M (record, +14.7% YoY); diluted EPS $0.08 vs $0.04
Net revenues for Q2 2025 hit $63.1M, a record high, up 14.7% from $55.0M in Q2 2024.
Viemed closes acquisition of Lehan's Medical Equipment for $26M base plus $2.2M earnout
Base purchase price $26M (subject to adjustments) plus estimated contingent consideration of ~$2.2M.
Viemed authorizes share repurchase of up to 1.98M shares (~5% of outstanding) through June 2026
Board authorized repurchase of up to 1,976,441 common shares (approx. 5% of outstanding) through June 2026.
Viemed reports Q1 2025 revenue of $59.1M, up 17% YoY; net income rises 64%
Q1 net revenues $59.1M, 17% increase from $50.6M in Q1 2024.
Viemed acquires Lehan's Medical Equipment for $26M base price; diversifies into women's health
Base purchase price $26M, plus ~$2.2M contingent payments; expected close Q3 2025.
Viemed posts record Q4 revenue $60.7M; full year net revenue $224.3M; issues 2025 guidance
Q4 net revenue $60.7M (+20% YoY); full year $224.3M (+23% YoY).
Viemed Healthcare Q3 2024: revenue up 17.4% to $58M, net income up 33%
Net revenues of $58.0M, a company record; up 17.4% YoY and 5.5% sequentially.
Viemed Q2 2024 revenue hits record $55.0M, up 27% YoY; Adjusted EBITDA up 31%
Net revenues $55.0M (record), up 27% YoY and 9% sequential from Q1 2024.
Viemed Q1 2024 revenue $50.6M, up 28% YoY; net income $1.6M
Net revenues $50.6M for Q1 2024, increase of $11.0M or 28% vs Q1 2023.
Viemed acquires majority stake in East Alabama HomeMed; expects ~$4M annual revenue
Transaction closed April 1, 2024; Viemed gains controlling interest and managerial control of HomeMed.
Viemed reports record Q4 revenue $50.7M (+35% YoY); net income up 43%
Q4 2023 revenue $50.7M, up 35% from $37.5M in Q4 2022; full-year revenue $183.0M, up 32%.
Viemed Healthcare reports record Q3 2023 revenue $49.4M (+38% YoY); net income up 177%
Net revenues of $49.4M, a Company record, up 38% YoY and 14% sequentially from Q2 2023.
Viemed Healthcare reports Q2 2023 record revenue of $43.3M, up 31% YoY
Net revenues of $43.3M for Q2 2023, a new Company record, up 31% YoY; HMP acquisition contributed $2.5M.
Viemed files HMP 2022 financials: $31.85M revenue, net loss $275K
HMP had 2022 revenue of $31.85M and net loss attributable to parent of $275K.
Viemed completes $28M acquisition of Home Medical Products; guides Q2 rev $42.5M-$43.5M
Acquired HMP for ~$28M cash; funded by $15M cash on hand and $13M from existing credit facilities.
Viemed Q1 2023 revenue record $39.6M, up 31% YoY; EBITDA $8.3M
Net revenue of $39.6M, a record, up 31% from Q1 2022 and 6% sequentially.
Viemed Healthcare to acquire Home Medical Products for $31.75M in cash
Purchase price of $31.75M cash for 100% equity; expected closing in June 2023.
Q4 core net revenue $37.5M (record), +30% vs Q4 2021, +5% sequentially.
Viemed wins complete overruling of OIG claims; $0 overpayment, funds returned
ALJ overturned all remaining disputed claims from OIG audit; Medicare contractors returned 100% of previously remitted funds.
Viemed enters $60M senior secured credit facilities with accordion up to $90M
New facilities: $30M revolving credit facility (5-yr) + $30M delayed draw term loan (5-yr), total $60M.
Viemed Q3 core revenue $35.8M, +28% YoY; ventilator patients up 11%
Core net revenue of $35.8M for Q3 2022, a record, +28% YoY and +7% sequential.
Viemed Healthcare Q2 2022 core revenue $33.1M record, up 26% YoY; adjusted EBITDA $6.5M
Q2 core net revenues $33.1M (record); total revenues including COVID-19 services $33.3M.
On April 14, 2025, Bruce Greenstein notified Viemed Healthcare, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors, effective immediately.
Max materiality 0.85 · Median 0.60 · Most common event earnings